


CURRENT **ACTIVITIES** BY PHARMA

ADDRESSING THE FIGHT WITH THE COVID-19 DISEASE

March 19, 2020 | UPharma Consulting | upharma-c.com/en/



COVID-19 DESCRIPTION

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China. @CDC

Organization	Type	Target	Phase	Current status & plans	Timeline	Source
GILEAD	Treatment	Remdesivir	III	Remdesivir is now being tested in five Covid-19 clinical trials that have been set up at breakneck speed.	CT results are expected in April 2020	link
SANOFI	Treatment + Vaccine	Plaquenil®	Preclinical	Conduct additional CTs and supply millions of doses of an existing anti-malaria product	N.a.	link
Pfizer BIONTECH	Treatment + Vaccine	New mRNA vaccine	Preclinical	Co-development of a new product clinical testing in humans. Germany's BioNTech uses strands of mRNA to spur the production of protective antibodies.	CTs are planned to be started in April 2020	link
Johnson & Johnson	Vaccine	Covid-19 vaccine	Preclinical	J&J is using the same vaccine platform it used to develop its Ebola vaccine	R&D – in Jan 2020 & CT to be started by the end of Nov 2020	link
QIAGEN	Test	RNA test		The company is looking to steeply ramp up its worldwide production from 1.5 mln COVID-19 tests/ month to 6.5 mln in April and to 10 mln in June 2020.	Started in February 2020	link
illumina®	R&D platform	Explyfy® – a DNA search engine		A platform to new next-generation sequencing workflows focused in microbiology and infectious disease, including for the novel coronavirus.	Started in March 2020	link
REGENERON	Treatment	Monoclonal antibody therapy	Preclinical	To select the top 2 antibodies for a cocktail therapy, which can either be administered to at-risk people before exposure as a vaccine or as treatment for those already infected.	Potential to enter human CT by early summer 2020	link
ascleptis	Treatment	Combination of two antivirals	I	The Chinese manufacturer is testing a combination of antivirals, one approved for HIV and one approved for hepatitis C, that might treat coronavirus infection	N.a.	link
Takeda	Treatment	Polyclonal antibody therapy	Preclinical	Collaboration with several health and regulatory agencies and health care partners across the globe on its TAK-888. The company is trying to access to source plasma from people who have successfully recovered from COVID-19	Started in March 2020	link
Roche	Test	cobas® SARS-CoV-2 test		Roche Diagnostics said that it has begun deploying its newly authorized cobas coronavirus diagnostic to hospitals and reference laboratories, with a wave of 400,000 swab-testing kits expected to arrive this week.	End of March 2020	link
moderna	Vaccine	mRNA-1273	I	A vaccine candidate was identified by Moderna just 42 days after the novel coronavirus was sequenced. The clinical trial started recruiting healthy participants in the first week of March.	CT results are expected in summer 2020	link
CanSinoBIO	Vaccine	Covid-19 vaccine	I	CanSino's approach involves taking a snippet of coronavirus' genetic code and entwining it with a harmless virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies.	CT to be started in March 2020	link
ARCTURUS therapeutics	Vaccine	Covid-19 vaccine	Preclinical	The company in partnership with Duke University plans to take an RNA virus that has been edited to encode for proteins that will protect against infection and load it into a liquid nanoparticle.	CT to be started in March-April 2020	link
AbCellera Lilly	Treatment	Antibody drug	Preclinical	Eli Lilly has partnered with a Canadian firm called AbCellera to develop antibody treatments for coronavirus infection. Using a blood sample from a coronavirus survivor, AbCellera identified more than 500 antibodies that might protect against the virus.	CTs in humans to be started in the next four months of 2020	link
gsk GlaxoSmithKline	Vaccine	Covid-19 vaccine	Preclinical	GSK is lending its technology to a Chinese – Clover Biopharmaceuticals – at work on a coronavirus vaccine. Clover's approach involves injecting proteins that spur an immune response, thereby priming the body to resist infection.	N.a.	link
inovio	Vaccine	Covid-19 vaccine	Preclinical	Inovio has spent the last four decades working to turn DNA into medicine, and the company believes its technology could quickly generate a vaccine for the novel coronavirus. The company has partnered with a Chinese manufacturer, Beijing Advaccine Biotechnology.	CTs are planned to be started in April 2020	link